July 30--Baxalta, a bioscience company spun off from Baxter International earlier this month, likes its prospects for the rest of the year.
The Deerfield-based company expects pro forma sales growth, excluding the impact of foreign currency, of 5 percent to 6 percent in the second half of 2015. Prior guidance provided in May called for sales growth of 2 percent to 3 percent.
Baxalta on Thursday also provided specific earnings guidance for the second half of 2015, expecting earnings before special items of $1.02 to $1.04 a share.
For the second quarter that ended June 30, the company only reported sales data because it was still a subsidiary of Baxter. In the quarter, Baxalta said revenue declined 2 percent to $1.43 billion.
Excluding the impact of the strong dollar, sales would have grown 7 percent, driven by robust demand for its hemophilia A treatment and immunoglobulin therapies.
asachdev@tribpub.com
